Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Gupta K, et al. Among authors: zhang q. J Manag Care Spec Pharm. 2018 Nov;24(11):1116-1127. doi: 10.18553/jmcp.2018.17488. Epub 2018 Sep 13. J Manag Care Spec Pharm. 2018. PMID: 30212268 Free PMC article.
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Amin A, et al. Among authors: zhang q. Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11. Curr Med Res Opin. 2017. PMID: 28635338
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.
Amin A, Keshishian A, Vo L, Zhang Q, Dina O, Patel C, Odell K, Trocio J. Amin A, et al. Among authors: zhang q. J Med Econ. 2018 Mar;21(3):244-253. doi: 10.1080/13696998.2017.1394866. Epub 2017 Nov 20. J Med Econ. 2018. PMID: 29047304 Free article.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. Amin A, et al. Among authors: zhang q. J Manag Care Spec Pharm. 2018 Sep;24(9):911-920. doi: 10.18553/jmcp.2018.24.9.911. J Manag Care Spec Pharm. 2018. PMID: 30156450 Free PMC article. Clinical Trial.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. Amin A, et al. Among authors: zhang q. J Manag Care Spec Pharm. 2020 May;26(5):639-651. doi: 10.18553/jmcp.2020.26.5.639. J Manag Care Spec Pharm. 2020. PMID: 32347184 Free PMC article.
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A, Keshishian A, Hines DM, Dina O, Le H, Rosenblatt L, Liu X, Zhang Q, Vo L. Amin A, et al. Among authors: zhang q. Curr Med Res Opin. 2022 Dec;38(12):2131-2140. doi: 10.1080/03007995.2022.2115772. Epub 2022 Aug 30. Curr Med Res Opin. 2022. PMID: 35993487
69,921 results
You have reached the last available page of results. Please see the User Guide for more information.